Single-dose tafenoquine to prevent relapse of plasmodium vivax malaria

• Main Authors: Marcus V.G. Lacerda, Alejandro Llanos-Cuentas, Srivicha Krudsood, Chanthap Lon, David L. Saunders, Rezika Mohammed, Daniel Yilma, Dhelio Batista Pereira, Fe E.J. Espino, Reginaldo Z. Mia, Raul Chuquiyauri, Fernando Val, Martín Casapía, Wuelton M. Monteiro, Marcelo A.M. Brito, Mônica R.F. Costa, Nillawan Buathong, Harald Noedl, Ermias Diro, Sisay Getie, Kalehiwot M. Wubie, Alemseged Abdissa, Ahmed Zeynudin, Cherinet Abebe, Mauro S. Tada, Françoise Brand, Hans Peter Beck, Brian Angus, Stephan Duparc, Jörg Peter Kleim, Lynda M. Kellam, Victoria M. Rousell, Siôn W. Jones, Elizabeth Hardaker, Khadeeja Mohamed, Donna D. Clover, Kim Fletcher, John J. Breton, Cletus O. Ugwuegbulam, Justin A. Green, Gavin C.K.W. Koh
• Other Authors: GlaxoSmithKline, USA
• Format: Article
• Published: 2020
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/51961
• Institution: Mahidol University

Copyright © 2019 Massachusetts Medical Society. BACKGROUND Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed “radical cure”). Tafenoquine is a single-dose 8-aminoqu...